Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 1501 AL 1515

DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease

Xu LZ, Li BQ, Jia JP.

Mol Neurobiol. 2019 Apr;56(4):2838-2844. doi: 10.1007/s12035-018-1242-2. Epub 2018 Jul 31.

Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis

Chan VTT, Sun Z, Tang S, Chen LJ, Wong A, Tham CC, Wong TY, Chen C, Ikram MK, Whitson HE, Lad EM, Mok VCT, Cheung CY.

Ophthalmology. 2019 Apr;126(4):497-510. doi: 10.1016/j.ophtha.2018.08.009. Epub 2018 Aug 13.

Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors

Takeda S.

Neurosci Res. 2019 Apr;141:36-42. doi: 10.1016/j.neures.2018.08.005. Epub 2018 Aug 16.

Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the (18)F-AV-1451 Tracer for Tau Imaging

He M, Baker SL, Shah VD, Lockhart SN, Jagust WJ.

IEEE Trans Med Imaging. 2019 Mar;38(3):697-709. doi: 10.1109/TMI.2018.2870441. Epub 2018 Sep 17.

Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology

Costa C, Romoli M, Liguori C, Farotti L, Eusebi P, Bedetti C, Siliquini S, Cesarini EN, Romigi A, Mercuri NB, Parnetti L, Calabresi P.

Neurobiol Aging. 2019 Jan;73:61-67. doi: 10.1016/j.neurobiolaging.2018.09.006. Epub 2018 Sep 18.

Subjective cognitive decline: preclinical manifestation of Alzheimer's disease

Lin Y, Shan PY, Jiang WJ, Sheng C, Ma L.

Neurol Sci. 2019 Jan;40(1):41-49. doi: 10.1007/s10072-018-3620-y. Epub 2018 Nov 5.

Impaired brain plasticity as a potential therapeutic target for treatment and prevention of dementia

Rajji TK.

Expert Opin Ther Targets. 2019 Jan;23(1):21-28. doi: 10.1080/14728222.2019.1550074. Epub 2018 Nov 30.

Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome

Rafii MS.

Dev Neurobiol. 2019 Jul;79(7):711-715. doi: 10.1002/dneu.22658. Epub 2018 Dec 16.

Natural Polyphenols in the Treatment of Alzheimer's Disease

Syarifah-Noratiqah SB, Naina-Mohamed I, Zulfarina MS, Qodriyah HMS.

Curr Drug Targets. 2018;19(8):927-937. doi: 10.2174/1389450118666170328122527.

Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update

Chaves S, Piemontese L, Hiremathad A, Santos MA.

Curr Med Chem. 2018;25(1):97-112. doi: 10.2174/0929867324666170330092304.

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies

Gao Y, Tan L, Yu JT, Tan L.

Curr Alzheimer Res. 2018;15(3):283-300. doi: 10.2174/1567205014666170417111859.

Targeting PPARalpha in Alzheimer's Disease

D'Orio B, Fracassi A, Ceru MP, Moreno S.

Curr Alzheimer Res. 2018 Feb 22;15(4):345-354. doi: 10.2174/1567205014666170505094549.

Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research

Jankowska A, Wesolowska A, Pawlowski M, Chlon-Rzepa G.

Curr Med Chem. 2018;25(17):2045-2067. doi: 10.2174/0929867324666170529122802.

The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview

Jakki SL, Senthil V, Yasam VR, Chandrasekar MJN, Vijayaraghavan C.

Curr Drug Targets. 2018;19(2):155-169. doi: 10.2174/1389450118666170612100750.

Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis

Mueller C, Perera G, Hayes RD, Shetty H, Stewart R.

Age Ageing. 2018 Jan 1;47(1):88-94. doi: 10.1093/ageing/afx098.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias